“This last time, it was about revenue for the S-
Post# of 36537
(Total Views: 271)
Posted On: 12/03/2020 7:39:25 PM
“This last time, it was about revenue for the S-1. That should be done and there should not be any reason that information has not been put in, since the deals have been done.
So, no reason for the S-1 not being approved now.”
Please don’t take offense. But all of the above has nothing to do with how S1s work. It’s hard to even follow. Generex endured a one year review of the 2019 K that Joe described as a deep dive. That held up Generex from having the S1s declared in Effect for nearly a year. That was detailed in the last update that it appears you never heard. Ngio on that end has 3 S1s. Two are all ready and all set. One that Joe will fill with his financing deal information that he was informed by the SEC will only be a limited review. That’s a positive. After a year delay due to SEC review, causing no funds to subsidiaries other than vaccines, it’s getting close to go time.
So, no reason for the S-1 not being approved now.”
Please don’t take offense. But all of the above has nothing to do with how S1s work. It’s hard to even follow. Generex endured a one year review of the 2019 K that Joe described as a deep dive. That held up Generex from having the S1s declared in Effect for nearly a year. That was detailed in the last update that it appears you never heard. Ngio on that end has 3 S1s. Two are all ready and all set. One that Joe will fill with his financing deal information that he was informed by the SEC will only be a limited review. That’s a positive. After a year delay due to SEC review, causing no funds to subsidiaries other than vaccines, it’s getting close to go time.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼